Legal Guide · Updated November 2026

Is Compounded Semaglutide Still Legal in 2026?

The legal status of compounded semaglutide has shifted several times since 2022. I have tracked this closely across 54+ telehealth providers. Here is where things stand as of November 2026, what it means for patients, and what your options are if you are on compounded semaglutide now.

The short version: the FDA declared the semaglutide shortage over on February 21, 2025, and the grace periods for compounders ended in spring 2025. Compounding a copy of Ozempic or Wegovy is now tightly limited. Narrow exceptions remain for patient-specific prescriptions where a prescriber documents a real clinical difference. This is general information, not legal advice.

A Quick History: How Compounded Semaglutide Became So Common

In 2022, semaglutide went on the FDA’s drug shortage list. Demand for Ozempic and Wegovy outran supply, and Novo Nordisk, the sole manufacturer of both drugs, could not keep up.

Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounders get much more room to copy an FDA-approved drug while it is on the shortage list. When semaglutide was listed, compounding pharmacies and the telehealth companies they supplied stepped in and sold copies at a fraction of the brand price. Our guide to the cheapest GLP-1 options tracks current pricing across providers.

The FDA Shortage List: What Changed

While a drug is on the shortage list, compounders have a clear legal basis to make copies of it. Once the FDA declares the shortage resolved, the FDA generally treats the drug as commercially available and that basis narrows sharply. Here is the timeline from the FDA’s own policy page for compounders:

2022: Semaglutide added to the FDA drug shortage list.
February 21, 2025: FDA determined that the shortage of semaglutide injection products (Ozempic and Wegovy) was resolved.
April 2025: After a federal court denied a request to block the decision on April 24, 2025, the FDA said its period of enforcement discretion for 503A pharmacies had ended.
May 22, 2025: End of the FDA’s enforcement discretion for 503B outsourcing facilities.
April 1, 2026: FDA updated its page to say semaglutide and tirzepatide do not appear on the 503B bulks list, and laid out how it judges whether a compounded drug is “essentially a copy.”

So the answer in 2026 is not in flux month to month. The shortage is over, and the exceptions that remain are narrow.

503A vs. 503B Pharmacies: A Critical Distinction

Federal law splits compounders into two groups, and the rules after the shortage differ for each.

503A pharmacies compound for individual patient prescriptions and are mainly overseen by state pharmacy boards. They may not compound drugs that are essentially copies of a commercially available drug “regularly or in inordinate amounts.” Per the FDA page, the agency treats a product as essentially a copy if it has the same active ingredient in a similar or substitutable strength and the same route of administration, unless the prescriber documents a significant difference for that patient. The FDA says it does not intend to act if a compounder fills four or fewer prescriptions of such a product in a calendar month.

503B outsourcing facilities register with the FDA, follow current Good Manufacturing Practices (cGMP), and can produce in bulk without patient-specific prescriptions. They may not compound a drug that is identical or nearly identical to an FDA-approved drug unless it is on the shortage list. They also may not use a bulk drug substance unless it is on the 503B bulks list or the drug is in shortage. Semaglutide is on neither list.

Feature	503A Pharmacy	503B Outsourcing Facility
Scale	Patient-specific prescriptions	Bulk production
Regulation	Primarily state boards	FDA-registered, cGMP
Copies of an available approved drug	Not “regularly or in inordinate amounts”	Not allowed unless the drug is in shortage
Semaglutide from bulk ingredient in 2026	Only within the limits above	Not on the 503B bulks list

Some compounders have marketed semaglutide mixed with vitamin B12 or other ingredients and argued the result is not a copy. The FDA’s April 2026 update uses an injectable semaglutide plus vitamin B12 (cyanocobalamin) product as an example of a combination it may still treat as essentially a copy. The exception that matters is a prescriber documenting a significant difference for the individual patient.

Novo Nordisk’s Legal Campaign Against Compounders

Novo Nordisk has pursued compounders, med spas, and telehealth sellers in court for years. As of August 2025, Novo had filed 132 lawsuits in federal courts across 40 states, resulting in 44 permanent injunctions. Those suits have alleged things like false or misleading marketing and, for some telehealth companies, violations of state corporate practice of medicine laws. Many of the orders have been entered by consent, and in August 2026 a federal judge in New York dismissed the false advertising claims in one Novo case with leave to amend, so results vary by case.

Regulators have also gone after marketing. In September 2025 the FDA sent warning letters to compounders and telehealth companies over claims about compounded GLP-1s, and in February 2026 it sent a further 30 warning letters to telehealth companies.

Compare GLP-1 providers and pricing

Browse Provider Directory →

What About Compounded Tirzepatide?

Tirzepatide, the active ingredient in Mounjaro and Zepbound, followed the same path a few months earlier. Per the FDA page, the FDA found the tirzepatide shortage resolved on October 2, 2024 and confirmed that decision on December 19, 2024. Enforcement discretion for 503A pharmacies ended in March 2025 after a court denied an injunction, and for 503B facilities on March 19, 2025. Like semaglutide, tirzepatide is not on the 503B bulks list.

Eli Lilly has pursued its own lawsuits against compounders and sellers. Our comparison of compounded vs. brand-name GLP-1s covers the broader differences.

What Happens to Patients on Compounded Semaglutide Now

If you still get compounded semaglutide from a telehealth provider, expect one of these:

Your provider may switch you. Many telehealth companies that built on compounded semaglutide now offer brand-name Wegovy or Ozempic through insurance or manufacturer self-pay programs.

Your pharmacy may stop filling. If yours stops, you will need another source or a brand-name prescription.

Enforcement has targeted sellers, not patients. The lawsuits and FDA letters described above were aimed at pharmacies, telehealth companies, and marketers. We are not aware of any action against an individual patient with a valid prescription. That is not legal advice.

The brand price has come down. The gap between compounded and brand-name self-pay prices is much smaller than it was in 2023. For cost strategies, see our GLP-1 cost guide and our guide to using FSA and HSA for GLP-1s.

The Price Gap: Compounded vs. Brand-Name in 2026

Brand-name semaglutide is far cheaper for cash payers than it was during the shortage. As of Nov 4, 2026, NovoCare Pharmacy lists these self-pay prices:

Option	Self-pay price per month	Notes
Wegovy pen, all doses up to 2.4 mg	$349	$199 for each of the first 2 fills of 0.25 mg or 0.5 mg for new patients, through Dec 31, 2026
Wegovy HD 7.2 mg pen	$399
Wegovy pill	$149 to $299	$149 for 1.5 mg, $199 for 4 mg, $299 for 9 mg and 25 mg
Ozempic pen 0.25 mg, 0.5 mg, 1 mg	$349	Same $199 intro offer through Dec 31, 2026
Ozempic pen 2 mg	$499

Compounded prices vary by provider and change often, so we do not quote a single range here. Check current prices on our cheapest GLP-1 page.

List prices matter if your insurance ties your coinsurance or deductible to them. Novo Nordisk has said it will cut the list price of Wegovy, Ozempic, and Rybelsus to $675 a month starting January 1, 2027, about 50% lower for Wegovy and 35% lower for Ozempic. Coverage varies by plan. Our insurance coverage guide and GLP-1 without insurance guide cover your options.

How to Verify Your Compounding Pharmacy Is Legitimate

If you do use a compounded product, check the pharmacy. The compounded product is not FDA-approved, so the pharmacy’s own quality control matters a lot.

Check state board licensing. Every compounding pharmacy must be licensed by the state pharmacy board where it operates. You can verify this on your state board of pharmacy website.

Look for accreditation. PCAB accreditation is voluntary. Not all legitimate pharmacies have it, but it is a positive signal.

Verify 503B registration with the FDA. The FDA keeps a public list of registered outsourcing facilities. If a pharmacy claims 503B status but is not on that list, that is a red flag.

Ask about testing. Reputable pharmacies test for potency, sterility (for injectables), and purity. Ask whether they can provide certificates of analysis.

Watch for these warning signs:

No requirement for a prescription or medical consultation
Claims that the product is “FDA-approved” (compounded drugs are not FDA-approved)
Inability to provide a pharmacy license number
Shipping from outside the United States
Products made with semaglutide sodium or semaglutide acetate. The FDA says these salt forms are different active ingredients from the approved drugs and it knows of no basis for compounding with them
Products sold “for research use only”

What You Should Do Now

Ask your provider where your medication comes from. Find out whether it is a 503A pharmacy or a 503B facility and what their plan is if that source stops.
Compare brand self-pay prices. Check the current NovoCare and telehealth self-pay prices against what you pay now.
Recheck your insurance. Coverage for brand-name GLP-1s varies by plan. Our provider directory shows which platforms help with insurance and prior authorizations.
Do not switch or stop on your own. Compounded doses are often measured differently from brand pens. Work out any change with your prescriber so you do not take the wrong amount.
Keep an active relationship with a licensed prescriber. That keeps your care continuous however the compounding market shifts.

FAQ

Is it legal to buy compounded semaglutide in 2026?

The FDA declared the semaglutide shortage resolved on February 21, 2025, and its grace periods for compounders have ended. 503A pharmacies may still compound for an individual patient within narrow limits, for example when a prescriber documents a significant clinical difference. 503B facilities cannot use semaglutide as a bulk ingredient because it is not on the shortage list or the 503B bulks list. Enforcement so far has targeted sellers, not patients. This is not legal advice.

What is the difference between 503A and 503B compounding pharmacies?

503A pharmacies compound for individual patient prescriptions and are mainly regulated by state boards. 503B outsourcing facilities register with the FDA, follow cGMP manufacturing standards, and can produce in bulk without patient-specific prescriptions.

Can Novo Nordisk sue me for using compounded semaglutide?

Novo Nordisk’s lawsuits have targeted compounding pharmacies, telehealth providers, med spas, and distributors. We are not aware of suits against individual patients with valid prescriptions. This is not legal advice.

Will compounded semaglutide be completely unavailable in 2026?

Not completely. 503A pharmacies can still compound for individual patients within the FDA’s limits. Large-scale copying of Ozempic and Wegovy is no longer permitted.

How do I switch from compounded to brand-name semaglutide?

Work with your prescriber. The active ingredient is the same, but compounded doses are often measured differently from brand pens, so your prescriber should set the brand dose and schedule. They can also help with insurance prior authorization. Many providers in our directory can help with the transition.

Guides:

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the FDA’s compounding policy page for semaglutide and tirzepatide, NovoCare Pharmacy self-pay prices, Novo Nordisk’s February 2026 list price announcement, and news and legal reports on Novo Nordisk lawsuits and FDA warning letters on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.